Healthcare Market Research Reports & Industry Analysis

Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.

Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.

The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.

Publications found: 71,946

Sort by:

Splenic Marginal Zone B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Splenic Marginal Zone B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Splenic Marginal Zone B-Cell Lymphoma Drugs in Development by Stages, Targ...

May 2022 54 pages

Squalene Monooxygenase (Squalene Epoxidase or SQLE or EC 1.14.14.17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Squalene Monooxygenase (Squalene Epoxidase or SQLE or EC 1.14.14.17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Squalene Monooxygena...

May 2022 37 pages

Squamous Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Squamous Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Squamous Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 165 pages

Squamous Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Squamous Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Squamous Non-Small Cell Lung Cancer Drugs in Development by Stages, Target,...

May 2022 148 pages

Squamous Non-Small Cell Lung Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Squamous Non-Small Cell Lung Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Squamous Non-Small Cell Lung Carcinoma Drugs in Development by Stages, Ta...

May 2022 43 pages

Staphylococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Staphylococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Staphylococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 301 pages

Staphylococcus aureus Alpha Hemolysin (Alpha Toxin or hly) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Staphylococcus aureus Alpha Hemolysin (Alpha Toxin or hly) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Staphylococcus aureus Alpha He...

May 2022 38 pages

Staphylococcus Aureus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Staphylococcus Aureus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Staphylococcus Aureus Infections Drugs in Development by Stages, Target, MoA, R...

May 2022 292 pages

Status Epilepticus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Status Epilepticus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Status Epilepticus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Pl...

May 2022 40 pages

Streptococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Streptococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Streptococcal Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ...

May 2022 60 pages

Streptococcal Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Streptococcal Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Streptococcal Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 115 pages

Stress Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Stress Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Stress Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecu...

May 2022 41 pages

Subacute Necrotizing Encephalomyelopathy (Leigh Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Subacute Necrotizing Encephalomyelopathy (Leigh Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Subacute Necrotizing Encephalomyelopathy (Leigh Disease...

May 2022 40 pages

Subarachnoid Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Subarachnoid Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Subarachnoid Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 43 pages

Substance (Drug) Abuse Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Substance (Drug) Abuse Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Substance (Drug) Abuse Drugs in Development by Stages, Target, MoA, RoA, Molecule Type an...

May 2022 88 pages

Substance P Receptor (Tachykinin Receptor 1 or NK 1 Receptor or NK1R or TACR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Substance P Receptor (Tachykinin Receptor 1 or NK 1 Receptor or NK1R or TACR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Substance...

May 2022 52 pages

Surface Protein gp120 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Surface Protein gp120 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Surface Protein gp120 Drugs in Development by Therapy Areas and Ind...

May 2022 62 pages

Surgical Wound Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Surgical Wound Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Surgical Wound Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 37 pages

Synaptic Functional Regulator FMR1 (Fragile X Mental Retardation Protein 1 or FMRP or FMR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Synaptic Functional Regulator FMR1 (Fragile X Mental Retardation Protein 1 or FMRP or FMR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMA...

May 2022 35 pages

Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Pl...

May 2022 51 pages

Systemic Candidiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Systemic Candidiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Systemic Candidiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Ke...

May 2022 55 pages

Systemic Idiopathic Juvenile Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Systemic Idiopathic Juvenile Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Systemic Idiopathic Juvenile Arthritis Drugs in Development by Stages, Ta...

May 2022 37 pages

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Systemic-Onset Juvenile Idiopathic Arthritis (Still...

May 2022 54 pages

Systolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Systolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Systolic Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type an...

May 2022 49 pages

T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY T-Cell Acute Lymphocytic Leukemia (T-Ce...

May 2022 79 pages

T-Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

T-Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY T-Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players...

May 2022 81 pages

T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Player...

May 2022 263 pages

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY T Cell Specific Surface Glycopro...

May 2022 58 pages

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3-Leu 4 Epsilon Chain or CD3E) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3-Leu 4 Epsilon Chain or CD3E) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Pla...

May 2022 43 pages

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4-Leu 3 or CD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4-Leu 3 or CD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY T Cell Surface G...

May 2022 49 pages

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Pl...

May 2022 43 pages

TAR DNA Binding Protein 43 (TDP43 or TARDBP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

TAR DNA Binding Protein 43 (TDP43 or TARDBP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY TAR DNA Binding Protein 43 (TDP43 or TARDBP)...

May 2022 51 pages

Tauopathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Tauopathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Tauopathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides...

May 2022 69 pages

Tay-Sachs Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Tay-Sachs Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Tay-Sachs Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Play...

May 2022 47 pages

Tenosynovial Giant Cell Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Tenosynovial Giant Cell Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Tenosynovial Giant Cell Tumor Drugs in Development by Stages, Target, MoA, RoA, Mo...

May 2022 42 pages

Testicular Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Testicular Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Testicular Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Play...

May 2022 46 pages

Thioredoxin (Trx or ATL Derived Factor or Surface Associated Sulphydryl Protein or TXN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thioredoxin (Trx or ATL Derived Factor or Surface Associated Sulphydryl Protein or TXN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY T...

May 2022 37 pages

Thromboangiitis Obliterans (Buerger Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Thromboangiitis Obliterans (Buerger Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Thromboangiitis Obliterans (Buerger Disease) Drugs in Development b...

May 2022 37 pages

Thrombocytopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Thrombocytopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Thrombocytopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Player...

May 2022 106 pages

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Pla...

May 2022 47 pages

Thrombosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thrombosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Thrombosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides a...

May 2022 151 pages

Thromboxane A2 Receptor (Prostanoid TP Receptor or TBXA2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thromboxane A2 Receptor (Prostanoid TP Receptor or TBXA2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Thromboxane A2 Receptor (Prost...

May 2022 36 pages

Thymic Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Thymic Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Thymic Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Player...

May 2022 70 pages

Thymic Stromal Lymphopoietin (TSLP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thymic Stromal Lymphopoietin (TSLP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Thymic Stromal Lymphopoietin (TSLP) Drugs in Developm...

May 2022 41 pages

Thymidine Kinase (TK or EC 2.7.1.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thymidine Kinase (TK or EC 2.7.1.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Thymidine Kinase (TK or EC 2.7.1.21) Drugs in Develo...

May 2022 38 pages

Thymidylate Synthase (TYMS or EC 2.1.1.45) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thymidylate Synthase (TYMS or EC 2.1.1.45) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Thymidylate Synthase (TYMS or EC 2.1.1.45) Dru...

May 2022 55 pages

Thymoma (Thymic Epithelial Tumor) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Thymoma (Thymic Epithelial Tumor) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Thymoma (Thymic Epithelial Tumor) Drugs in Development by Stages, Target, MoA,...

May 2022 81 pages

Thyrotropin Receptor (Thyroid Stimulating Hormone Receptor or TSHR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thyrotropin Receptor (Thyroid Stimulating Hormone Receptor or TSHR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Thyrotropin Receptor...

May 2022 35 pages

Tissue Type Plasminogen Activator (t Plasminogen Activator or Alteplase or Reteplase or Plasminogen-Activator Kringle or PLAT or EC 3.4.21.68) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tissue Type Plasminogen Activator (t Plasminogen Activator or Alteplase or Reteplase or Plasminogen-Activator Kringle or PLAT or EC 3.4.21.68) Drugs in Development by Therapy Areas and Indications, St...

May 2022 39 pages

Toll Like Receptor 2 (Toll-Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Toll Like Receptor 2 (Toll-Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Toll L...

May 2022 59 pages

Filters

Clear all

Price

—

Date

—

Pages

—

Offers

33% OFF on “TCR-Based Antibody a...

Discount Offer from GMD Research

280

Special Offer from MP Advisors

Special Offer on Therapy Class R...